You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 162 No. 18, October 14, 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (174)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Hypertension
 •Neurology
 •Dementias
 •Alert me on articles by topic

The Prevention of Dementia With Antihypertensive Treatment

New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study

Françoise Forette, MD; Marie-Laure Seux, MD; Jan A. Staessen, MD, PhD; Lutgarde Thijs, MSc; Marija-Ruta Babarskiene, MD; Speranta Babeanu, MD; Alfredo Bossini, MD; Robert Fagard, MD; Blas Gil-Extremera, MD; Tovio Laks, MD; Zhanna Kobalava, MD; Cinzia Sarti, MD; Jaakko Tuomilehto, MD; Hannu Vanhanen, MD; John Webster, MD; Yair Yodfat, MD; Willem H. Birkenhäger, MD; for the Syst-Eur Investigators

Arch Intern Med. 2002;162:2046-2052.

Background  After the double-blind, placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial ended in February 1997, randomized patients were offered active study medication for a further period of observation.

Objective  To refine the estimates of the long-term effects of antihypertensive therapy on the incidence of dementia.

Methods  Eligible patients had no dementia and were at least 60 years old. Their systolic blood pressure at entry was 160 to 219 mm Hg, with diastolic blood pressure below 95 mm Hg. Antihypertensive therapy was started immediately after randomization in the active treatment group, but only after termination of the double-blind trial in the control patients. Treatment consisted of nitrendipine (10-40 mg/d), with the possible addition of enalapril maleate (5-20 mg/d), hydrochlorothiazide (12.5-25 mg/d), or both add-on drugs.

Results  Median follow-up increased from 2.0 years in the double-blind trial to 3.9 years overall. The incidence of dementia doubled from 32 to 64 cases, 41 of whom had Alzheimer disease. Throughout follow-up, systolic/diastolic blood pressure was 7.0/3.2 mm Hg higher in the 1417 control patients than in the 1485 subjects randomized to active treatment. At the last examination, the blood pressure difference was still 4.2/2.9 mm Hg; 48.1%, 26.4%, and 11.4% of the control patients were taking nitrendipine, enalapril, and/or hydrochlorothiazide, whereas in the active treatment group these proportions were 70.2%, 35.4%, and 18.4%, respectively. Compared with the controls, long-term antihypertensive therapy reduced the risk of dementia by 55%, from 7.4 to 3.3 cases per 1000 patient-years (43 vs 21 cases, P<.001). After adjustment for sex, age, education, and entry blood pressure, the relative hazard rate associated with the use of nitrendipine was 0.38 (95% confidence interval, 0.23-0.64; P<.001). Treatment of 1000 patients for 5 years can prevent 20 cases of dementia (95% confidence interval, 7-33).

Conclusion  The extended follow-up of Syst-Eur patients reinforces the evidence that blood pressure–lowering therapy initiated with a long-acting dihydropyridine protects against dementia in older patients with systolic hypertension.


From the Department of Geriatrics, Hôpital Broca, University of Paris V, Paris, France (Drs Forette and Seux); Study Coordinating Centre, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium (Drs Staessen and Fagard and Ms Thijs); Institute of Cardiology, Kaunas, Lithuania (Dr Babarskiene); National Institute Ana Aslan, Bucharest, Romania (Dr Babeanu); Centro Ipertensione Policlinico Umberto I, Rome, Italy (Dr Bossini); Facultad de Medicina, Universidad de Granada, Granada, Spain (Dr Gil-Extremera); Tallinn Central Hospital, Tallinn, Estonia (Dr Laks); Department of Internal Diseases, Municipal Clinical Hospital, Moscow, Russian Federation (Dr Kobalava); Department of Epidemiology and Health Promotion, National Public Health Institute, and Department of Public Health, University of Helsinki, Helsinki, Finland (Drs Sarti and Tuomilehto); Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (Dr Vanhanen); Aberdeen Royal Hospitals, University of Aberdeen, Aberdeen, Scotland (Dr Webster); Department of Family Medicine, Hadassah Medical School, Hebrew University of Jerusalem, Jerusalem, Israel (Dr Yodfat); and Erasmus University, Rotterdam, the Netherlands (Dr Birkenhäger).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial
Saxby et al.
Neurology 2008;70:1858-1866.
ABSTRACT | FULL TEXT  

High-Normal Blood Pressure Is Associated With Poor Cognitive Performance
Knecht et al.
Hypertension 2008;51:663-668.
ABSTRACT | FULL TEXT  

Biomarkers of cerebrovascular disease in dementia
MILLS et al.
Br. J. Radiol. 2007;80:S128-S145.
ABSTRACT | FULL TEXT  

Arterial aging: pathophysiological principles
O'Rourke
Vasc Med 2007;12:329-341.
ABSTRACT  

Modern concept of vascular cognitive impairment
Bowler
Br Med Bull 2007;83:291-305.
ABSTRACT | FULL TEXT  

Mechanical Factors in Arterial Aging: A Clinical Perspective
O'Rourke and Hashimoto
J Am Coll Cardiol 2007;50:1-13.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration
Ellul et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:233-239.
ABSTRACT | FULL TEXT  

Less Atherosclerosis and Lower Blood Pressure for a Meaningful Life Perspective With More Brain
Staessen et al.
Hypertension 2007;49:389-400.
FULL TEXT  

Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?
Robinson et al.
Stroke 2007;38:441-450.
ABSTRACT | FULL TEXT  

When two are worse than one: Stroke and Alzheimer disease
DeCarli
Neurology 2006;67:1326-1327.
FULL TEXT  

Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42.
Stenset et al.
Neurology 2006;67:830-833.
ABSTRACT | FULL TEXT  

Vascular disease and risk factors, rate of progression, and survival in Alzheimer's disease.
Bhargava et al.
J Geriatr Psychiatry Neurol 2006;19:78-82.
ABSTRACT  

Antihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian et al.
Arch Neurol 2006;63:686-692.
ABSTRACT | FULL TEXT  

Reducing the Risk of Dementia: Efficacy of Long-Term Treatment of Hypertension
Peila et al.
Stroke 2006;37:1165-1170.
ABSTRACT | FULL TEXT  

White matter lesions and cognition: It's time for randomized trials to preserve intelligence
Hill and Mitchell
Neurology 2006;66:470-471.
FULL TEXT  

Pitfalls in blood pressure measurement in daily practice
Houweling et al.
Fam Pract 2006;23:20-27.
ABSTRACT | FULL TEXT  

One hundred years of Alzheimer's disease and the neglected second lesson of Alois Alzheimer on multicausality in dementia
Rikkert et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2005;20:269-272.
 

Does Blood Pressure Control Contribute to a More Successful Aging?
Benetos
Hypertension 2005;46:261-262.
FULL TEXT  

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention
Verdecchia et al.
Hypertension 2005;46:386-392.
ABSTRACT | FULL TEXT  

APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study
Dufouil et al.
Neurology 2005;64:1531-1538.
ABSTRACT | FULL TEXT  

William M. Feinberg Lecture: Cognitive Vitality and the Role of Stroke and Cardiovascular Disease Risk Factors
Gorelick
Stroke 2005;36:875-879.
ABSTRACT | FULL TEXT  

Nonlinear Relations of Blood Pressure to Cognitive Function: The Baltimore Longitudinal Study of Aging
Waldstein et al.
Hypertension 2005;45:374-379.
ABSTRACT | FULL TEXT  

Antihypertensive Therapy Increases Cerebral Blood Flow and Carotid Distensibility in Hypertensive Elderly Subjects
Lipsitz et al.
Hypertension 2005;45:216-221.
ABSTRACT | FULL TEXT  

Update in Neurology
Samuels
ANN INTERN MED 2005;142:28-36.
FULL TEXT  

Cross-Sectional and Longitudinal Association Between Antihypertensive Medications and Cognitive Impairment in an Elderly Population
Hajjar et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2005;60:67-73.
ABSTRACT | FULL TEXT  

Mixed Dementia: Emerging Concepts and Therapeutic Implications
Langa et al.
JAMA 2004;292:2901-2908.
ABSTRACT | FULL TEXT  

Cognitive Impairment and Blood Pressure: Quo Usque Tandem Abutere Patientia Nostra?
Staessen and Birkenhager
Hypertension 2004;44:612-613.
FULL TEXT  

Risk Factors for Vascular Dementia and Alzheimer Disease
Gorelick
Stroke 2004;35:2620-2622.
ABSTRACT | FULL TEXT  

Medication Undertreatment in Assisted Living Settings
Sloane et al.
Arch Intern Med 2004;164:2031-2037.
ABSTRACT | FULL TEXT  

Systolic Hypertension in Older Persons
Chaudhry et al.
JAMA 2004;292:1074-1080.
ABSTRACT | FULL TEXT  

Decline in Blood Pressure Over Time and Risk of Dementia: A Longitudinal Study From the Kungsholmen Project
Qiu et al.
Stroke 2004;35:1810-1815.
ABSTRACT | FULL TEXT  

Chronic Management of Blood Pressure After Stroke
Pedelty and Gorelick
Hypertension 2004;44:1-5.
FULL TEXT  

Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment
Erkinjuntti et al.
Stroke 2004;35:1010-1017.
ABSTRACT | FULL TEXT  

Predictors of Cognitive Decline and Mortality of Aged People Over a 10-Year Period
Tilvis et al.
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M268-M274.
ABSTRACT | FULL TEXT  

Vascular Cognitive Impairment
Bowler
Stroke 2004;35:386-388.
FULL TEXT  

Circle of Willis Atherosclerosis Is a Risk Factor for Sporadic Alzheimer's Disease
Roher et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:2055-2062.
ABSTRACT | FULL TEXT  

Measures of Obesity Are Associated With Vascular Stiffness in Young and Older Adults
Wildman et al.
Hypertension 2003;42:468-473.
ABSTRACT | FULL TEXT  

Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD
Qiu et al.
Neurology 2003;61:655-660.
ABSTRACT | FULL TEXT  

Cognitive and Physical Disabilities and Aging-Related Complications of Diabetes
Gregg and Brown
Clin. Diabetes 2003;21:113-118.
ABSTRACT | FULL TEXT  

Commentary: Aging Well and Aging Poorly: Primary and Secondary Low Blood Pressure
Harris
J. Gerontol. A Biol. Sci. Med. Sci. 2003;58:M662-664.
FULL TEXT  

Outcome beyond blood pressure control?
Staessen et al.
Eur Heart J 2003;24:504-514.
FULL TEXT  

Antihypertensive Treatment May Prevent Dementia
JWatch Psychiatry 2003;2003:13-13.
FULL TEXT  

Antihypertensive Treatment May Prevent Dementia
JWatch Neurology 2002;2002:3-3.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.